サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1702411

無菌注射剤の世界市場 (2025-2033年)

Global Sterile Injectable Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
無菌注射剤の世界市場 (2025-2033年)
出版日: 2025年04月10日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の無菌注射剤の市場規模は、2024年の6億1,666万米ドルから、予測期間中はCAGR 7.4%で推移し、2032年には11億7,435万米ドルに達すると予測されています。

慢性疾患の有病率の増加が予測期間中に無菌注射剤市場の成長を大きく促進すると見込まれています。糖尿病、癌、心疾患などの疾患は世界的にますます広がっており、これらの多くは継続的な治療を必要とします。例えば、2023年のICMR INDIABの調査によると、インドでは約1億100万人が糖尿病を患っていると報告されています。さらに、癌は年間約1,000万人の死因となっており、世界的な主要な健康問題の一つとなっています。

多くの慢性疾患は注射がもっとも有効な薬剤で治療されます。これは、血流への迅速な吸収、長時間の治療効果、または特定の部位への標的投与が必要とされるためです。無菌注射剤は、こうした疾患の管理において重要な役割を果たしており、効果的な治療に不可欠な存在です。これらの疾患が今後も増加していく中で、無菌注射剤の需要はさらに高まり、市場の拡大が予測期間中に加速すると考えられています。

当レポートでは、世界の無菌注射剤の市場を調査し、市場概要、市場成長への各種影響因子の分析、各種区分・地域/主要国別の詳細分析、主要企業のプロファイルなどをまとめています。

目次

第1章 市場概要・市場範囲

第2章 エグゼクティブインサイト・重要ポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 分子タイプ別概要
  • 薬剤タイプ別概要
  • 用途別概要
  • 地域別概要

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーとパイオニア
  • CXOによる見解
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析・価格動向
  • キーオピニオンリーダー

第5章 無菌注射剤市場：分子タイプ別

  • 低分子
  • 高分子

第6章 無菌注射剤市場：薬剤タイプ別

  • モノクローナル抗体
  • インスリン
  • 免疫グロブリン
  • サイトカイン
  • 血液因子
  • その他

第7章 無菌注射剤市場：用途別

  • 腫瘍
  • 心血管疾患
  • 感染症
  • 糖尿病
  • その他

第8章 無菌注射剤市場：地域別の市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要・主要企業
  • 市場シェア分析・ポジショニングマトリックス
  • 戦略的パートナーシップ・M&A
  • 製品ポートフォリオとイノベーションにおける主な展開
  • 企業ベンチマーキング

第10章 企業プロファイル

  • Pfizer Inc.
  • Amgen Inc.
  • GSK Plc
  • Merck &Co., Inc.
  • Novartis AG
  • Sanofi
  • Bausch Health Companies
  • Gilead Sciences, Inc.
  • Hikma Pharmaceuticals P
  • Cipla Inc.

第11章 仮定・調査手法

第12章 付録

目次
Product Code: MD617

The global sterile injectable market reached US$ 616.66 million in 2024 and is expected to reach US$ 1,174.35 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Sterile injectables are medications or biologics that are administered through injections and are manufactured under stringent conditions to ensure they are free from any microorganisms. These products are commonly used to treat a wide range of medical conditions, especially those requiring rapid action or precise delivery to specific parts of the body. Sterile injectables are often preferred for conditions such as cancer, diabetes, autoimmune diseases, and infections.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is expected to significantly drive the growth of the sterile injectables market over the forecast period. Conditions such as diabetes, cancer, and heart disease are becoming more widespread globally, and many of these diseases require ongoing treatment. For example, the 2023 ICMR INDIAB study reported that 10.1 crore people in India are living with diabetes. Additionally, cancer is responsible for around 10 million deaths annually, making it one of the leading global health concerns.

Many chronic diseases are treated with medications that are most effective when administered through injection. This is often due to the need for rapid absorption into the bloodstream, extended therapeutic action, or targeted delivery to specific areas of the body. Sterile injectables play a critical role in managing these conditions, making them essential for effective therapy. As these conditions continue to rise, the demand for sterile injectables is expected to grow, driving market expansion during the forecast period.

High Manufacturing Costs

The high production costs associated with sterile injectables often result in higher drug prices, which can limit patient access, especially in regions with weaker healthcare infrastructure or limited insurance coverage. This creates a significant barrier for patients in need of these medications, reducing the overall market potential. Additionally, the high costs of production can cut into profit margins, leaving fewer resources available for investment in research and development (R&D) of new drugs and innovative delivery systems. This can slow the development of new treatment options and hinder the market's ability to reach new patient populations.

Unlike simpler forms of medication like tablets, sterile injectables require complex manufacturing processes to maintain sterility. This added complexity demands specialized skills, more manpower, and additional quality control measures, all of which drive up production costs. As a result, these factors are expected to limit the growth of the sterile injectables market.

Segment Analysis

The global sterile injectable market is segmented based on molecule type, drug type, application, and region.

Molecule Type:

Large molecule in the molecule type segment is expected to dominate the sterile injectable market.

The large molecules segment is expected to dominate the sterile injectable market due to their targeted approach in treating chronic diseases. These biologics are designed to precisely target specific molecules or pathways, offering more effective treatments with fewer side effects compared to traditional small-molecule drugs. Their complex structures allow for high specificity, reducing off-target effects and improving safety profiles.

Additionally, large-molecule biologics often have immunomodulatory effects, making them especially beneficial for autoimmune diseases. The ability to tailor treatment plans based on individual patient characteristics further enhances their therapeutic outcomes. These advantages are expected to maintain the segment's dominant position in the market throughout the forecast period.

Geographical Analysis

North America is expected to dominate the sterile injectable market.

North America is expected to maintain its dominant position in the sterile injectable market. North America has a strong regulatory framework that ensures the safety, efficacy, and quality of sterile injectables. Regulatory bodies like the FDA play a crucial role in approving and monitoring the use of sterile injectables, providing a secure environment for both manufacturers and consumers.

Additionally, significant investments from major market players in the region are also expected to contribute to the overall regional market growth. For instance, in February 2024, Simtra BioPharma Solutions announced a $250 million investment to expand its sterile fill/finish manufacturing campus in Bloomington, Indiana, which will include state-of-the-art facilities for high-speed automated syringe and vial filling lines.

Additionally, in June 2021, Jubilant HollisterStier, a subsidiary of Jubilant Pharmova Limited, invested $92 million to increase its sterile injectable manufacturing capacity in Spokane, WA, which will enhance production by 50%.

Alongside these investments, the growing prevalence of chronic diseases and the increasing adoption of sterile injectables are further boosting the market in the region. These factors combined are expected to solidify North America's dominant position in the sterile injectable market throughout the forecast period.

Competitive Landscape

The global market players in the sterile injectable market include Pfizer Inc., Amgen Inc., GSK Plc, Merck & Co., Inc., Novartis AG, Sanofi, Bausch Health Companies Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals PLC, and Cipla Inc., among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global sterile injectable market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Molecule Type
  • 2.4. Snippet by Drug Type
  • 2.5. Snippet by Application
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Chronic Diseases
      • 3.1.1.2. Increasing Investments and Development of New Products by Pharmaceutical Companies
    • 3.1.2. Restraints
      • 3.1.2.1. Side Effects Associated with the Sterile Injectables
      • 3.1.2.2. High Manufacturing Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Innovation in Drug Delivery Methods
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Sterile Injectable Market, By Molecule Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
    • 5.1.2. Market Attractiveness Index, By Molecule Type
  • 5.2. Small Molecule*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Large Molecule

6. Sterile Injectable Market, By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Monoclonal Antibodies*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Insulin
  • 6.4. Immunoglobulin
  • 6.5. Cytokines
  • 6.6. Blood factors
  • 6.7. Others

7. Sterile Injectable Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Oncology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cardiovascular Diseases
  • 7.4. Infectious Diseases
  • 7.5. Diabetes
  • 7.6. Others

8. Sterile Injectable Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Pfizer Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Amgen Inc.
  • 10.3. GSK Plc
  • 10.4. Merck & Co., Inc.
  • 10.5. Novartis AG
  • 10.6. Sanofi
  • 10.7. Bausch Health Companies
  • 10.8. Gilead Sciences, Inc.
  • 10.9. Hikma Pharmaceuticals P
  • 10.10. Cipla Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us